InFlectis BioScience SAS, a drug discovery company committed to the development of innovative therapeutics harnessing the Integrated Stress Response for the treatment of a broad range of diseases, today announced that the French National Agency for Medicines and Health Products Safety (ANSM) approved the Company’s Clinical Trial Application (CTA) to begin a Phase 1 study of IFB-088 (study P-188) (Press Release).

InFlectis BioScience SAS, a biopharmaceutical company specializing in the discovery and development of drugs to treat orphan and non-orphan protein conformational disorders, today announced the strengthening of its intellectual property portfolio in Europe and in the USA with the issuance of two patents (Press Release).

InFlectis BioScience SAS and Laboratoire de Génétique Médicale de Strasbourg (UMRS 1112 – Inserm – Université de Strasbourg, France) today announced the signature of a 3-year research partnership and a license agreement for the development and marketing of a novel pharmacological therapy approach for retinal degeneration in ciliopathies (Press Release).

InFlectis BioScience announced the completion of a Series A financing round amounting to €6 million to accelerate the clinical development of its drug candidate IFB-088 (Press Release). The financing was co-led by CM-CIC INNOVATION and REMIGES VENTURES with the participation of its historic shareholders, GO CAPITAL and PARTICIPATIONS BESANÇON.

InFlectis BioScience is pleased to announce today that European Commission has granted orphan drug designation to its drug candidate IFB-088 for the treatment of Charcot-Marie-Tooth disease (Press Release).

InFlectis BioScience is pleased to announce today that the US FDA has granted orphan drug designation to its drug candidate IFB-088 for the treatment of Charcot-Marie-Tooth disease (Press Release).